Cytomedix Announces In-Depth Interview with CEO and Chairman Kshitij Mohan, Ph.D.

Strategic Insights -

Cytomedix, Inc., a biotechnology company specializing in the research, development, and licensing of products for treating non-healing chronic wounds, announced that The Wall Street Transcript has published an in-depth interview with Chief Executive Officer and Chairman Kshitij Mohan, Ph.D. The interview is available on the Cytomedix website or to subscribers at The Wall Street Transcript's website. During the interview, Dr. Mohan discussed the company's AutoloGel System, which addresses a large market for treating chronic and acute wounds.

Key Takeaways:

  • Cytomedix is a biotechnology company specializing in processes and products derived from autologous platelet releasates for treating wounds and other applications.
  • The company's AutoloGel System is a technology that utilizes an autologous platelet gel composed of multiple growth factors and fibrin matrix.
  • The Company has concluded the treatment phase of a blinded, prospective, multi-center clinical trial on the use of its technology in healing diabetic foot ulcers.
  • Dr. Mohan noted that the chronic and acute wound market is under-served by current products, and Cytomedix is addressing this unmet clinical need through its technology.
  • Cytomedix is licensing its technology to other companies, aiming to expand the market and increase awareness of the company's products.
  • Dr. Mohan expressed cautious optimism regarding the outcome of the ongoing audit of the clinical trial data, stating that patients treated strictly according to the protocol will achieve positive results.

Statistics:

  • The chronic and acute wound market is a large and under-served market, according to Dr. Mohan.
  • Cytomedix has concluded a blinded, prospective, multi-center clinical trial on the use of its AutoloGel System in healing diabetic foot ulcers.
  • The Company expects to complete the ongoing audit of the clinical trial data before the end of the year.

Sources:

  • The Wall Street Transcript
  • Cytomedix, Inc. (C) 2005 PRIMEZONE, All rights reserved
  • Securities and Exchange Commission (SEC) reports by Cytomedix, Inc.